Kalm Therapeutics is at the forefront of developing an innovative treatment for eczema and psoriasis through its flagship product, the Kalm Patch. This prescription patch is designed to cover affected skin areas, providing protection against scratching, infection, and moisture loss, which are known to exacerbate these conditions. The Kalm Patch features a proprietary formulation that delivers a continuous therapeutic dose of a natural, anti-inflammatory small molecule to the epidermis over a 24-hour period. This once-a-day application represents a significant advancement over traditional treatments, such as steroids and topical creams, which often require multiple daily doses and do not offer protective benefits.

In addition to its protective and therapeutic functions, the Kalm Patch incorporates a plant-based active pharmaceutical ingredient that is microbiome-balancing, aimed at reducing disease progression. This unique approach not only addresses the symptoms of eczema and psoriasis but also targets underlying factors that contribute to these skin conditions. By combining effective treatment with skin protection and microbiome support, Kalm Therapeutics is positioning the Kalm Patch as a comprehensive solution for patients seeking relief from chronic skin disorders.

United States

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

Kalm Therapeutics

Company Details